ANAB - AnaptysBio, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $0.89
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$66.57
DETAILS
HIGH:
$140.00
LOW:
$36.00
MEDIAN:
$56.00
CONSENSUS:
$66.57
UPSIDE:
20.14%
Market Cap:
1.53B
Volume:
223,699
Avg Volume:
477,353
52 Week Range:
13.99-57.73
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.35
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
136
IPO Date:
2017-01-26
EPS (TTM):
-5.12
P/E Ratio:
-2.59
Revenue (TTM):
91.28M
Total Assets:
483.83M
Total Debt:
369.46M
Cash & Equiv:
123.08M
Rev Growth (5Y):
62.7%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-21.7%
Debt/Equity:
5.21
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-04 | $0.52 | $-1.06 | +149.1% | $76.3M | $87.1M | -12.4% |
| 2025-08-06 | $-1.34 | $-1.50 | +10.7% | $22.3M | $20.8M | +6.9% |
| 2025-05-05 | $-1.28 | $-1.30 | +1.5% | $27.8M | $9.9M | +181.4% |
| 2025-02-27 | $-0.72 | $-1.61 | +55.3% | $43.1M | $7.8M | +453.9% |
| 2024-11-05 | $-1.14 | $-1.72 | +33.7% | $30.0M | $8.5M | +254.0% |
| 2024-08-05 | $-1.71 | $-1.20 | -42.5% | $11.0M | $24.3M | -54.9% |
| 2024-05-09 | $-1.64 | $-1.54 | -6.5% | $7.2M | $4.0M | +80.8% |
| 2024-03-11 | $-1.59 | $-1.74 | +8.6% | $9.0M | $2.0M | +343.6% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 91.28M | 17.16M | 10.29M | 63.17M | 75.00M | 8.00M | 5.00M | 10.00M | 16.68M | 17.57M | 15.84M | 5.48M |
| Net Income | (145.23M) | (163.62M) | (128.72M) | (57.80M) | (19.93M) | (97.34M) | (61.66M) | (30.07M) | (4.26M) | (5.41M) | 232,000 | (5.54M) |
| EPS | -5.12 | -6.08 | -4.57 | -2.11 | -0.73 | -3.60 | -2.50 | -1.52 | -0.23 | -0.38 | 0.25 | -2.28 |
| Total Assets | 483.83M | 452.39M | 610.38M | 643.07M | 416.55M | 435.20M | 509.00M | 329.36M | 62.18M | 56.28M | 25.07M | 3.91M |
| Total Debt | 369.46M | 17.81M | 19.45M | 20.95M | 342,000 | 2.90M | 8.26M | 14.45M | 13.81M | 4.92M | 4.92M | 932,000 |
| Cash & Equivalents | 123.08M | 35.97M | 71.31M | 495.73M | 250.46M | 171.02M | 113.60M | 81.19M | 51.23M | 51.68M | 22.19M | 2.81M |
| Operating Cash Flow | (135.34M) | (120.80M) | (73.59M) | (45.92M) | (14.16M) | (69.52M) | (48.51M) | (19.44M) | (9.03M) | (9.67M) | 14.60M | (5.80M) |
| Free Cash Flow | (135.69M) | (121.61M) | (73.95M) | (47.29M) | (14.73M) | (70.32M) | (49.57M) | (19.73M) | (9.08M) | (9.91M) | 14.46M | (5.83M) |
| FCF per Share | -4.78 | -4.52 | -2.63 | -1.72 | -0.54 | -2.60 | -2.01 | -1.00 | -3.44 | -3.88 | 0.38 | -5.24 |
| Book Value | 70.87M | 88.10M | 262.10M | 356.43M | 396.73M | 405.01M | 486.37M | 307.58M | 39.27M | 42.34M | 5.99M | 145,000 |
| Cash & ST Investments | 385.37M | 390.90M | 441.24M | 548.10M | 393.65M | 374.23M | 427.08M | 248.41M | 51.23M | 51.68M | 22.19M | 2.81M |
| ROC Equity | -2.05 | -1.86 | -0.49 | -0.16 | -0.05 | -0.24 | -0.13 | -0.10 | -0.11 | -0.13 | 0.04 | -38.24 |